Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

NCT ID: NCT05236387

Last Updated: 2024-02-09

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 14 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-03-01
• Study Completion Date: 2023-06-30

Brief Summary

The purpose of the present study is to evaluate the ability of 99mTc-TM to identify the clipped node after neoadjuvant chemotherapy (NAC) and to compare this percentage with historical national data. This study will also evaluate pain and discomfort after injection and pathological features of clipped nodes and any additional nodes removed.

Detailed Description

This is a phase 4 single-center, open-label, single-arm study evaluating the ability of 99mTc-TM to identify clipped nodes in primary breast cancer patients receiving NAC and subsequent Sentinel Lymph Node Biopsy (SLNB) as practice compared to published historical data . Sixty-four (64) patients (≥18 years) diagnosed with breast cancer and who are evaluated as having a favorable response (i.e., at least partial clinical response in the breast) to chemotherapy during the mid-treatment evaluation will be evaluated in this study. Patients will have suspicious lymph nodes assessed and one biopsied for pathological evaluation and clipped during the course of the patients' medical work-up. Patients will undergo NAC treatment and have a mid-treatment evaluation to assess response to the chemotherapy. Patients with a favorable response will complete NAC followed by identification of the clipped node and sentinel lymph nodes and standard lymph node assessment. Patients with an unfavorable response (i.e., no response to the NAC) will continue NAC but will not continue to participate in the study. All study patients undergoing SLNB will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) preoperatively. If no signal is detected within 30-60 minutes, patients may also be injected with BD (up to 10 cc), intraoperatively. Pain at injection site will be assessed pre-injection and at 1 minute after the 99mTc-TM injection.

It is anticipated that the majority of patients enrolled will receive NAC treatment. Although chemotherapy will be the primary neoadjuvant treatment used in this study, if the investigator feels the patient will benefit more from hormonal therapy, a hormonal treatment will be administered.

Conditions

Breast Cancer

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Intent to Treat group

All patients meeting entrance criteria, injected with 99m Tc-TM, and having one or more lymph nodes removed for which the pathologist confirms the type (lymph node versus non-lymph node) and contents (e.g., tumor cells) of the excised tissues will comprise the intent-to-treat population (ITT). This definition also carries over to the lymph nodes; i.e., nodes used for the ITT analysis must come from patients included in the ITT population. The ITT population will serve as the analysis population for all efficacy endpoints, unless indicated otherwise in the description of analyses.

99m Tc-TM

Intervention Type: DRUG

Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.

Interventions

99m Tc-TM

Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.

Intervention Type: DRUG

Other Intervention Names

Lymphoseek

Eligibility Criteria

Inclusion Criteria

1. The patient has provided written informed consent with HIPAA authorization.

2. The patient is female or male and ≥18 years of age at the time of consent.

3. The patient has been diagnosed with invasive Stage 2-3 breast cancer (T1-3; N1-2).

4. The patient has no history of inflammatory breast cancer.

5. The patient has no matted node on examination (N3).

6. The patient is eligible for neoadjuvant chemotherapy (NAC).

7. The patient is a candidate for surgical intervention, with sentinel lymph node assessment being a part of the surgical plan.

8. If of childbearing potential, the patient has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.

9. The patient has no known allergies or hypersensitivity to 99mTc-TM, BD, or India ink.

Exclusion Criteria

1. The patient is pregnant or lactating.

2. The patient has clinical and/or radiological evidence of metastatic or systemic disease. Oligo metastatic disease is acceptable (one organ and controlled).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cardinal Health

INDUSTRY

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mehran Habibi, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins Bayview

Locations

Johns Hopkins Bayview Hospital

Baltimore, Maryland, United States

Countries

United States

Other Identifiers

IRB00154162

Identifier Type: -

Identifier Source: org_study_id